Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Labcorp Holdings Inc. (NYSE: LH), a global provider of innovative and comprehensive laboratory services. These documents offer detailed information about the company’s operations, financial condition, governance and material events.
Labcorp’s recent current reports on Form 8-K include disclosures about quarterly and annual financial results, updated guidance and capital allocation decisions such as cash dividends on its common stock. Other 8-K filings describe participation in investor conferences, appointments and retirements of directors and executives, and transactions affecting parts of its business, such as the sale of select early development medical device testing assets.
Filings also confirm that Labcorp’s common stock, with a par value of $0.10 per share, is registered under Section 12(b) of the Securities Exchange Act and trades on the New York Stock Exchange under the symbol LH. Segment information released through earnings-related filings outlines performance for the Diagnostics Laboratories and Biopharma Laboratory Services segments, providing context on demand for clinical testing and biopharma laboratory services.
On Stock Titan, Labcorp’s SEC filings are updated as they become available from EDGAR. AI-powered summaries help explain the key points in complex documents, so readers can quickly understand items such as results of operations, changes in leadership, dividend declarations and significant transactions. Users can review Forms 8-K for material events, as well as other core filings like annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials when they are filed.
For investors, analysts and other interested readers, this page serves as a focused entry point into Labcorp’s regulatory disclosures, combining real-time updates with AI-generated highlights to make the information easier to interpret.
Labcorp (NYSE: LH) entered into a $1.0 billion senior unsecured revolving credit facility that replaces its 2021 agreement and pushes final maturity from April 2026 to June 27 2030. The Fourth Amended and Restated Credit Agreement, led by Bank of America, also adds a $500 million accordion, a $100 million swingline, and a $150 million L/C sub-limit.
Pricing is floating: (i) SOFR + 0.805%–1.300% or (ii) base rate + 0–0.300%, plus a facility fee of 0.070%–0.200%, all tiered to long-term debt ratings. Key covenant requires a net leverage ratio ≤ 4.0×, expandable to 4.5× for four quarters following material acquisitions (unlimited leverage-holiday elections subject to reset conditions). As of closing, no amounts are drawn. The agreement contains customary reps, covenants, and default provisions.
Labcorp Holdings (NYSE: LH) filed a Form 8-K disclosing that it will release its second-quarter 2025 financial results before market open on Thursday, July 24, 2025. Management will host a conference call and webcast at 9 a.m. ET the same day. The filing contains no preliminary results, strategic updates or other material information.